The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 103 results
Sort by date: Ascending
Jul 2024
Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens
The Journal of Clinical Psychiatry
AUTHOR(S)
Sommi RW, Saklad SR, Weiden PJ, Still D, Wang M, Yagoda S
View on PubMed
Clinical
Schizophrenia
Jul 2024
Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients
Frontiers in Psychiatry
AUTHOR(S)

Simmons A, O'Sullivan AK, Carpenter-Conlin J, Carty MK, Saucier C, McDonnell D

View on PubMed
Real World Evidence
Schizophrenia
Aug 2024
Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
BMC Psychiatry
AUTHOR(S)

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M

View on PubMed
Real World Evidence
Bipolar Disorder
Schizophrenia
Dec 2024
Opioid antagonists: clinical utility, pharmacology, safety, and tolerability
CNS Spectrums
AUTHOR(S)

McIntyre RS, Harris ME, Todtenkopf MS, Akerman S, Burgett J

View on PubMed
Review/Commentary
General
Dec 2024
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
The Journal of Clinical Psychiatry
AUTHOR(S)

Ballon JS, Kahn RS, Arevalo C, Dunbar M, McDonnell D, Correll CU

View on PubMed
Clinical
Bipolar Disorder
Schizophrenia
Jan 2025
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies
The Journal of Clinical Psychiatry
AUTHOR(S)
Correll CU, Doane MJ, McDonnell D, Akerman S, Saklad SR
View on PubMed
Clinical
Bipolar Disorder
Schizophrenia
Mar 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Citrome L, Correll CU, Cutler AJ, Dunbar M, Hoberg AR, Hopkinson C, Mattingly GW, McGrory JA, Rege B, Weiden PJ, McDonnell D
View on PubMed
Review/Commentary
Schizophrenia
Apr 2025
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Citrome L, Dunbar M, McGrory JA
View on PubMed
Clinical
Schizophrenia
Apr 2025
Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder
The American Journal on Addictions
AUTHOR(S)

Grebla R, Kauf TL, Lax A, Cook EE, Lin Y, Liu J, Liu S, O'Sullivan AK, Shi L, Shi S, Sullivan MA, Swallow E, Witkiewitz K, Drexler K

View on PubMed
Real World Evidence
Alcohol Use Disorder
May 2025
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Advances in Therapy
AUTHOR(S)
Lauriello J, Doane MJ, McGrory JA, Hughes AG, Strand LN
View on PubMed
Real World Evidence
Schizophrenia